A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

NCT06001086 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Disitamb Vedotin ,pyrotinib

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]